A Novel Triterpenoid Isolated from the Root Bark of Ailanthus
                        excelsa Roxb (Tree of Heaven), AECHL-1 as a Potential Anti-Cancer
                    Agent by Lavhale, Manish S. et al.
A Novel Triterpenoid Isolated from the Root Bark of
Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a
Potential Anti-Cancer Agent
Manish S. Lavhale
1., Santosh Kumar
2., Shri Hari Mishra
1, Sandhya L. Sitasawad
2*
1Pharmacy Department, Faculty of Technology and Engineering, The M. S. University of Baroda, Vadodara, Gujarat, India, 2National Centre for Cell Science, NCCS
Complex, University of Pune Campus, Ganeshkhind, Pune, Maharashtra, India
Abstract
Background: We report here the isolation and characterization of a new compound Ailanthus excelsa chloroform extract-1
(AECHL-1) (C29H36O10; molecular weight 543.8) from the root bark of Ailanthus excelsa Roxb. The compound possesses anti-
cancer activity against a variety of cancer cell lines of different origin.
Principal Findings: AECHL-1 treatment for 12 to 48 hr inhibited cell proliferation and induced death in B16F10, MDA-MB-
231, MCF-7, and PC3 cells with minimum growth inhibition in normal HEK 293. The antitumor effect of AECHL-1 was
comparable with that of the conventional antitumor drugs paclitaxel and cisplatin. AECHL-1-induced growth inhibition was
associated with S/G2-M arrests in MDA-MB-231, MCF-7, and PC3 cells and a G1 arrest in B16F10 cells. We observed
microtubule disruption in MCF-7 cells treated with AECHL-1 in vitro. Compared with control, subcutaneous injection of
AECHL-1 to the sites of tumor of mouse melanoma B16F10 implanted in C57BL/6 mice and human breast cancer MCF-7 cells
in athymic nude mice resulted in significant decrease in tumor volume. In B16F10 tumors, AECHL-1 at 50 mg/mouse/day
dose for 15 days resulted in increased expression of tumor suppressor proteins P53/p21, reduction in the expression of the
oncogene c-Myc, and downregulation of cyclin D1 and cdk4. Additionally, AECHL-1 treatment resulted in the
phosphorylation of p53 at serine 15 in B16F10 tumors, which seems to exhibit p53-dependent growth inhibitory responses.
Conclusions: The present data demonstrate the activity of a triterpenoid AECHL-1 which possess a broad spectrum of
activity against cancer cells. We propose here that AECHL-1 is a futuristic anti-cancer drug whose therapeutic potential
needs to be widely explored for chemotherapy against cancer.
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Introduction
According to the World Health Organization based on
morbidity, mortality, economic burden, and emotional hardship,
cancer may be considered the most onerous health problem
afflicting people worldwide [1]. Currently, over 22.4 million
people in the world are suffering from cancer. Approximately 10.1
million new cases are diagnosed with cancer annually, and more
than 6.2 million die of the disease in the year 2000 [2]. This
represents an increase of around 19% in incidence and 18% in
mortality since 1990. An important aim of cancer research is to
find therapeutic compounds having high specificity for cancerous
cells/tumor and fewer side effects than the presently used
cytostatic/cytotoxic agents.
Numerous plant-derived compounds used in cancer chemo-
therapy include vinblastine, vincristine, camptothecin derivatives,
etoposide derived from epipodophyllotoxin, and paclitaxel (taxolH)
[3]. However most of these compounds exhibit cell toxicity and
can induce genotoxic, carcinogenic and teratogenic effects in non-
tumor cells, and some of them failed in earlier clinical studies [4,5].
Another most widely used metal-based drug at present against
selected types of cancers is cisplatin [6], but use of cisplatin in
curative therapy was associated with some serious clinical
problems, such as severe normal tissue toxicity and resistance to
the treatment [7]. These side effects limit their use as
chemotherapeutic agents despite their high efficacy in treating
target malignant cells. Consequently, new therapies and treatment
strategies for this disease are necessary for treating patients with
this disease. Therefore, the search for alternative drugs that are
both effective in the treatment of cancers as well as non-toxic to
normal tissue is an important research line [8].
Terpenoids are used extensively for their aromatic qualities.
They play a role in traditional herbal remedies and are under
investigation for antibacterial, antineoplastic, and other pharma-
ceutical functions. Natural triterpenoids, such as oleanolic acid
and ursolic acid, are compounds with anti-tumorigenic and anti-
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such as 2-Cyano-3, 13 dioxooleana-1,9(11)-dien-28-oic acid
(CDDO) [10] and its derivative 1-[2-cyano-3-,12-dioxooleana-
1,9(11)-dien-28-oyl] imidazole (CDDO-Im) [11] also have anti-
tumor activity. Root bark of Ailanthus excelsa Roxb (Tree of
Heaven), a tree belonging to family Simaroubaceae is widely used in
Ayurveda as evidenced by phytotherapy [12]. Other species from
this family are well known for their anti-cancer activities [13].
Chemical constituents of A. excelsa include some triterpenes and
alkaloids [14]. In the present study we have evaluated the in vitro
and in vivo anti-cancer activity of a novel triterpenoid, AECHL-1
isolated from the root bark of the plant and found to be highly
effective in cancer cells of different lineage.
Materials and Methods
Isolation and characterization of AECHL-1
The root bark of A. excelsa was botanically verified by Professor
Shrihari Mishra (one of the authors in the present manuscript) and
the extraction and fractionation of air-dried powdered root bark
was done using chloroform. Isolation of AECHL-1 was done using
silica gel column chromatography and characterized by ultra
violet (Shimadzu 1700), infra red (Perkin Elmer Spectrum RX1),
nuclear magnetic resonance (Bruker Avance I NMR Spectrom-
eter) and mass spectroscopy (by Jeol SX 102 mass spectrometer).
The purity of the AECHL-1 was assessed by HPLC on a RP C-18
Phenomenex column using methanol-water (90:10, volume for
volume) as the mobile phase. The purified compound, AECHL-1
was dissolved in DMSO as stock solutions.
Cell lines
Normal human embryonic kidney cell line (HEK 293), mouse
melanoma B16F10 cells (B16F10), human breast carcinoma
(MDA-MB-231), human breast adeno-carcinoma (MCF-7) and
human prostate (PC3) cells were obtained from ATCC (Manassas,
VA). HEK 293, MCF-7 and B16F10 cells were cultured in
Dulbecco’s modified Eagle’s medium and PC3 in Ham’s F-12
media (Gibco) at 37uC under 5% CO2. MDA-MB-231 cells were
cultured in Leibovitz’s L-15 (Gibco) supplemented with 10% FCS
(Gibco), 100 units/ml penicillin and 100 mg/ml streptomycin in a
humidified atmosphere at 37uC.
Cell viability assay
Direct interference between different concentrations of
AECHL-1 (0–200 mM) and MTT in a cell-free system was not
observed, therefore, MTT assay was used to test cell viability in the
current system. HEK 293, B16F10, PC3, MCF 7 and MDA-MB-
231 cells (4610
3/well) were cultured in 96-well plates and after
24 h treated with different concentrations of AECHL-1 (0–
200 mM), cisplatin (0–100 mM) or paclitaxel (0–50 mM) for 12,
24, and 48 hr at 37uC. Cell viability was assessed by MTT
(0.5 mg/ml) conversion as described previously [15].
Cell proliferation assay
Proliferation of MCF-7 cells was determined by measuring (
3H)
thymidine incorporation. Briefly, aliquots of complete medium
containing 4610
3 cells were distributed into 96-well tissue culture
plates. After 24 hr, the media were replaced with various
concentrations of the AECHL-1 (0–100 mM), cisplatin (0–
100 mM) or paclitaxel (0–50 mM). Six hours after the treatment
1 mCi/well (
3H) thymidine (Board of Radiation and Isotope
Technology, Mumbai, India) was added and the cultures were
incubated further for 42 hr at 37uC. Cells were rinsed and
collected in scintillation mixture, and radioactivity incorporated
into the DNA was determined with a liquid scintillation counter
(Canberra Packard).
Annexin V-FITC binding assay
B16F10, MDA-MB-231 and MCF-7 cells (3610
5/ml) were
treated with various concentrations of AECHL-1 (0–40 mM) for
24 hr at 37uC. Cells were harvested after 24 hr, apoptosis was
detected by using Annexin V-FITC apoptosis detection Kit
(Calbiochem, USA) with flow cytometry (FACS Vantage–BD
Sciences, USA). The data was analyzed using Cell Quest software
for determining the percent of apoptotic cells.
Cell cycle analysis
B16F10, PC3, MDA-MB-231 and MCF-7 cells (3610
5/ml)
were treated with various concentrations of AECHL-1 (0–
100 mM), or paclitaxel (0–10 mM) for 24 hr. Cell cycle analysis
was performed as described earlier [16], with flow cytometry
(FACS Vantage–BD Sciences, USA). The data was analyzed using
Cell Quest software.
Immunocytochemistry
MCF-7 cells were fixed with 3.7% paraformaldehyde, and then
incubated with anti-a-tubulin antibodies (1:10000; Sigma, St.
Louis, MO). After the antibodies were washed off, the cells were
incubated with alexa-conjugated secondary antibodies (1:200;
Sigma, St. Louis, MO). Images were captured with a confocal laser
scanning microscope (Zeiss LSM510).
Animal tumor models
Male C57BL/6 (6–8 weeks of age) and female athymic nude
mice, NIH, nu/nu Swiss (10 weeks) were maintained in
accordance with the Central Animal Ethical Committee proce-
dures and guidelines. B16F10 melanoma cells were harvested,
suspended in PBS, and subcutaneously injected into the right flank
(2610
6 cells/flank) of C57BL/6 mice and MCF-7 cells (5610
6
cells/flank) into female athymic nude mice. Each athymic mouse
was implanted subcutaneous with a 0.72-mg of 17-b-estradiol
pellets, 2 weeks before inoculation of MCF-7 cells [17,18]. Tumor
size was measured every 3–4 days by a caliper and tumor volumes
determined by the length (L) and the width (W): V=(LW
2)/2 [19].
After two weeks, AECHL-1 (50 mg), AECHL-1 (100 mg), cisplatin
(100 mg) and PBS as vehicle control were injected subcutaneously
to the site of tumor for 15 days in C57BL/6 mice (n=6) and
AECHL-1 (5 mg), AECHL-1 (10 mg), paclitaxel (20 mg) and PBS
as vehicle control were injected subcutaneously to the site of tumor
per day for 10 days in female athymic nude mice (n=6). Tumor
volume was measured at regular interval during the study. At the
end of the experiment tumor and other organs were dissected out
for histological analyses and western blots.
Immunohistochemistry
Tissues and organs of C57BL/6 and nude mice were fixed in
alcohol formalin for 24 hr and embedded in paraffin as previously
described [20]. Tissue sections (5 mm) were stained with hematox-
ylin and eosin (H & E), visualized and photographed with an
inverted microscope (Nikon, ECLIPSE, TE2000-U, Japan).
Immunoblotting
Tumor tissue was homogenized in RIPA buffer (20 mM Tris–
HCl pH 7.5, 120 mM NaCl, 1.0% Triton 6100, 0.1% SDS, 1%
sodium deoxycholate, 10% glycerol, 1 mM EDTA and 16
protease inhibitor cocktail, Roche) proteins were isolated in
solubilized form and concentrations were measured by Bradford
Anticancer Activity of AECHL-1
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denatured in 26 SDS-PAGE sample buffer (sigma), resolved in
10% SDS–PAGE and transferred to nitrocellulose membrane
followed by blocking of membrane with 5% nonfat milk powder
(w/v) in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween 20).
The membranes were incubated with rabbit polyclonal anti-p21
and anti-pp53 antibodies (1:1000; Santa Cruz, CA), mouse
monoclonal anti-CDK4, anti-Cyclin D1 antibodies (1:1000; Cell
Signaling Technology, Beverly, MA), mouse monoclonal anti-c-
Myc antibody and mouse monoclonal anti-p53 antibody (1:1000;
Abcam, USA), followed by HRP-conjugated appropriate second-
ary antibodies and visualized by an enhanced chemiluminescence
(Pierce) detection system. Membranes were stripped and re-probed
with b-actin primary antibody (1:10000; MP Biomedicals, Ohio,
USA) as a protein loading control.
Statistics
The data reported for tumor volumes are expressed as mean6-
SEM. Statistical differences were determined by ANOVA and post
test applied was Tukey-Kramer multiple comparison Test.
Results
Chemistry: Ultraviolet, infra red, nuclear magnetic
resonance, and mass characterization of AECHL-1
IR (KBr): 3425, 3419 (hydroxyl group), 2972, 2966, 2923, 2873
(alkyl C-H stretch), 1733 (d lactone), 1718 (Bi acetyl), 1680 (C=O
conjugation with alkene), 1652 (-C=C stretching), 1600 (aromat-
ic), 1492, 1454, 1394 (methyl stretching), 1222 (d lactone), 1184,
1110, 1051, 1031 (acetals), 1018 nm (alkanes).
1H-NMR (DMSO,
400 Hz) d: 0.95 (3H, t,4 9-CH3), d:1.15 (3H, d, H-24), d:1.235 (3H,
d, 59-CH3), d: 1.5 (2H, ddd, 59-CH2), d: 1.73 (3H, ddd, H-21), d:
1.83 (1H, s, H-9), d: 1.87 (1H, s, H-14), d: 1.9 (2H, s, H-18), d:
2.16 (3H, s, H-18), d: 2.3 (3H, d, H-19) d: 2.71 (2H, s, H-20), d:
3.45 (2H, dd, H-23), d:3.65 (2H, d, H-22), d: 3.95 (1 H, t, H-12), d:
4.05 (2H, s, H-22), d: 5.30 (1H, s, H-15), d: 5.46 (1H, s, OH-2), d:
5.73 (1H, d,OH-29), d: 6.89 (1H, s, H-3), d: 8.82 (1H, s, OH-11).
Fast atom bombardment mass spectroscopy: m/z: 1068 due to
dimmer formation. The actual (M
+) was considered to be 543.8,
463.3 (M-C4H1O2), 461.4 (M-C4H2O2), 459.4 (M-C4H4O2),
361.2 (M-C9H11O4) (Figure 1B) and Mass Spectra (Figure S1).
AECHL-1 is a solid, mp. 248–250uC possessed a molecular
formula of C29 H36O10 as indicated by EI and ES mass spectra.
The IR spectrum showed the presence of hydroxyl (s) (3425 nm,
3419 nm), d lactone (1733 nm), and aromatic moiety (1600 nm).
The UV spectrum gave a characteristic absorption maximum at
235 nm, indicating the presence of auxochromic groups like
hydroxyl and ketone. The
1H-NMR spectrum of AECHL-1
revealed the presence of an aromatic proton d 6.89 and a singlet at
d 5.30 which is characteristic of the ester function at C-15. H-22
appeared as an AB system as a singlet at d 4.05 and doublet at d
3.65 and H-12 appeared as a triplet at d 3.95. The methyl group
H-19 on the aromatic ring appeared as singlet at d 2.3. A doublet
at d 1.235 for six protons is assigned at H-59. H-49 appeared as a
triplet at d 0.95. The methyl group, H-18 appeared as a singlet at
d 2.16 (Figure 2).
Inhibition of cell viability, proliferation, and apoptosis by
AECHL-1
Effect of AECHL-1 on the viability of B16F10, PC3, MDA-MB-
231 and MCF-7 cells was assessed. AECHL-1 inhibited cell
growth of MCF-7 cells in a concentration- and time-dependent
manner by MTT assay (Figure 3A). AECHL-1 inhibited cell
growth in different cancer cell lines with a minimum growth
inhibition in HEK 293 at 48 hr (Figure 3B). HEK 293 treated with
200 mM AECHL-1 exhibited high survival rate (.90%) as
compared to cancer cells. AECHL-1 was found to be more
effective on MCF-7 in comparison with B16F10, PC3 and MDA-
MB-231 in cell proliferation inhibition as observed by the (
3H)
thymidine uptake after 48 hr (Figure 3C). Moreover, AECHL-1
was found to be more potent than paclitaxel or cisplatin in cell
proliferation inhibition in MCF-7 cells after 48 hr (Figure 3D).
Annexin V-conjugated FITC and propidium iodide (PI) stain
was used to analyze the total percentage of apoptotic cells induced
Figure 1. Purity of AECHL-1 as assessed by HPLC. Single peak indicated that the preparation was .99% pure.
doi:10.1371/journal.pone.0005365.g001
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(Annexin V-FITC positive, PI negative), cells that are in late
apoptosis (Annexin V-FITC and PI positive), the necrotic cells (PI
positive only) and cells that are viable (Annexin V-FITC and PI
negative). Total percentage of apoptotic cells increased up to
36.25% and 37.18% at 20 mM in B16F10, MDA-MB-231 cells
respectively and 60.66% at 5 mM in MCF-7 cells (Figure 4).
AECHL-1 induced cell cycle arrest in cancer cells
To determine the phase of the cell cycle at which AECHL-1
exerts its growth-inhibitory effect, exponentially growing B16F10,
PC3, MDA-MB-231 and MCF-7 cells were treated with different
concentrations of AECHL-1 for 24 hr and analyzed by flow
cytometry (Table 1). We observed that B16F10 cells treated with
AECHL-1 showed an increase in the population in G1 phase
(52.18–72.08 %) with a concomitant decrease in the percentage of
cells in S-G2/M phase (47.98–26.16%), suggesting a G1 arrest. In
contrast, the number of PC3, MDA-MB-231 and MCF-7 cells in
S-G2/M phase increased from 42.91% to 57.62%, 49.40% to
77.16% and 45.13% to 70.97% respectively in response to
treatment with AECHL-1 and a decreased in G1 phase from
55.65% to 39.02%, 49.54% to 22.82%, 53.67% to 27.85%
Figure 2. Structure of AECHL-1 with its mass fragments by NMR spectroscopy.
doi:10.1371/journal.pone.0005365.g002
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MDA-MB-231 and MCF-7 cells. Paclitaxel treatment showed an
increase in the population of MCF-7 cells in G2/M phase (29.30%
to 72.55%) with a decrease in the percentage of cells in G1 phase
(48.30% to 4.62%) suggesting a growth arrest in G2/M phase
(Table 1). These results suggest that inhibition of cell cycle
progression could be one of the molecular events associated with
selective anti-cancer efficacy of AECHL-1 in cancer cells.
Effect of AECHL-1 on cellular microtubules
Microtubule staining in control and cells treated with AECHL-1
and paclitaxel, showed that both AECHL-1 and paclitaxel resulted
in microtubule disruption with an increase in the density of cellular
microtubules and formation of thick microtubule bundles
surrounding the nucleus in comparison to the untreated control
cells (Figure 5).
Effect of AECHL-1 on primary tumor volume in allograft
and xenograft
We also examined the effects of AECHL-1 on the in vivo
growth of primary tumors. Our preliminary studies showed that,
of the various doses of AECHL-1 (0.5 to 5 mg/kg) injected
intraperitoneal in C57BL/6 mice, the maximum tolerated dose
was a single dose of 0.5 mg/kg that showed no obvious sign of
toxicity when observed for one month. On this basis, the dose that
was chosen was 50 and 100 mg/kg/day (a dose that was 10–20%
of this maximum tolerated dose). On day 18 significant increase in
tumor volume in control group (p,0.001) and a regression in
tumor volume was evident in mice treated with 50 mg AECHL-1
(44.30365.20 % (p,0.001)) and with 100 mg AECHL-1
(51.01461.27% (p,0.001)). Tumors treated with 100 mg cisplatin
showed a reduction of tumor volume (93.1360.539% (p,0.001)).
However, AECHL-1 (50 mg) vs. AECHL-1 (100 mg) was found to
Figure 3. Growth inhibition and cell proliferation of different tumor cell lines by AECHL-1 in vitro. (A) Cell growth by MTT assay in MCF-7
cells were treated with different concentrations of AECHL-1 (10, 20, 40 and 100 mM) for 12, 24 and 48 hr and cell viability was determined by MTT
assay; (B) Cell growth by MTT assay in B16F10, PC3, MDA-MB-231 MCF-7 and HEK-293 cells. Cells were treated with different concentrations of AECHL-
1 (10, 20, 40 100 and 200 mM) for 48 hr, and cell viability was determined by MTT assay; (C) Cell proliferation by (
3H) thymidine incorporation in
B16F10, PC3, MDA-MB-231, and MCF-7 cells. Cells were treated with different concentrations of AECHL-1 (10, 20, 40 and 100 mM) for 48 hr, and cell
proliferation was determined by (
3H) thymidine incorporation; (D) Comparison of AECHL-1 with other chemotherapeutic drugs. MCF-7 cells were
treated with different concentrations (5, 10, 20, and 50 mM) of paclitaxel, cisplatin and AECHL-1 for 48 hr, and cell proliferation was determined by
(
3H) thymidine incorporation. Data are means6SEM of three independent experiments.
doi:10.1371/journal.pone.0005365.g003
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(50 mg) and AECHL-1 (100 mg) treated mice showed further
increase in tumor volume (p,0.001) but mice treated with
cisplatin showed reduction in tumor volume (p,0.001). However,
although cisplatin showed further reduction in tumor volume, the
damage caused to other organs was more than that in the
AECHL-1 (50 & 100 mg) treated group in C57BL/6 mice
(Figure 6A and 6B).
Since the cytotoxic doses of AECHL-1 for MCF-7 cells in vitro
were very low, the doses selected for tumor xenografts in female
athymic nude mice injected with MCF-7 cells were 5 and 10 mg.
These doses showed regression in tumor volume as: 35.7260.05%
for 5 mg( p ,0.001) and 28.5560.06% for 10 mg( p ,0.001)
whereas tumors treated with 20 mg paclitaxel showed a regression
in tumor volume (14.1960.32% (p,0.05)), which was less than the
AECHL-1 treated group (Figure 6C and 6D).
Effects of AECHL-1 treatment on tumor suppressor and
cell cycle regulatory proteins in Tumor allograft of
C57BL/6 Mice
We evaluated the effect of AECHL-1 treatment on the
expression of the tumor suppressor protein p53, the cell cycle
regulatory protein Cyclin D and cdk4 and the oncogene c-Myc. As
shown in Figure 4E, AECHL-1 at 50 mg/mouse/day administered
to B16F10-implanted tumors in C57BL/6 mice resulted in an
increase in the expression of wild-type p53 protein and then
decreased at a higher concentration (100 mg/mouse/day). The
level of the p53 was greater in the AECHL-1-treated group than in
the cisplatin-treated group, indicating that the antitumor action of
AECHL-1 was different from cisplatin. Since phosphorylation at
the Ser-15 residue of p53 is critical for p53-dependent activation of
cell cycle regulatory proteins for G1 arrest, we determined the
phosphorylation status of p53 and cyclin D1 and cdk4. AECHL-1
treatment resulted in an increase in phosphorylation of p53 at
serine 15 residue in tumors at 50 mg/mouse/day with a
concomitant increase in the level of p21 and decreased at
100 mg/mouse/day. Western blot analysis revealed that treatment
with 50 and 100 mg/mouse/day AECHL-1 caused a significant
reduction in the cycle-regulatory proteins cyclin D1 and cdk4.
Treatment with 50 and 100 mg/mouse/day AECHL-1 also
caused a significant reduction in the oncogene c-Myc thus
indicating that inhibition of the cell cycle may be responsible for
antitumor effects of AECHL-1 (Figure 7).
Histological analysis of tumor tissue and other organs in
C57BL/6 mice
Histological examination of tumor in C57BL/6 control mice
showed well developed blood vessels, increased neovascularization,
cell density and presence of hemorrhagic areas with probable signs
of angiogenesis with increased possibility of metastasis
(Figure 8.1A). Treatment of tumors with 50 mg AECHL-1 did
not show much influence on the tumor vascularization but showed
less occurrence of hemorrhagic areas, decrease in tumor cell
density and occurrence of picnotic/necrotic cells in the center of
the tumor (Figure 8.1B). Treatment with 100 mg AECHL-1
showed increase in necrotic cells, disappearance of neovascular-
ization, hemorrhagic areas and low cell density compared to
control (Figure 8.1C), thus indicating that AECHL-1 prevented
Figure 4. Effect of AECHL-1 on apoptosis of tumor cells. Detection of apoptosis was done by the Annexin V-FITC apoptosis detection kit
according to the manufacturer’s instructions and then analyzed by flow cytometry: UR indicates the percentage of late apoptotic cells (Annexin V and
PI positive cells), and LR indicates the percentage of early apoptotic cells (Annexin V positive cells) The data are presented in dot blots depicting
annexin/fluorescein isothiocyanate (x axis) vs. PI staining (y axis). The percentage of cells in each quadrant is shown. The results are representative of
three independent experiments.
doi:10.1371/journal.pone.0005365.g004
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neovascularization. Cisplatin treated group showed significant
increase in necrotic cells, decrease in tumor cell density and
volume (Figure 8.1D).
Compared with control, the heart tissue of the mice treated with
50 mg AECHL-1 showed normal structure while 100 mg showed
extensive myocardial fiber necrosis and contraction bands. The
fragmentation and smudging of the muscle fibers characteristic of
coagulative necrosis was seen (Figure 8.1E–8.1G). Cisplatin
treated mice also showed necrosis of myocardial fiber, slight
lymphocytic infiltration and also fragmentation and smudging of
the muscle fibers (Figure 8.1H).
Compared with control, the kidney of the mice treated with
50 mg AECHL-1 showed slight tubular vacuolization and tubular
dilation with hemorrhagic areas with normal glomeruli appearing
at the lower part. Treatment with 100 mg AECHL-1 showed
tubular vacuolization, tubular dilation, hemorrhagic condition and
scattered chronic inflammatory cell infiltrates (Figure 8.1I–8.1K).
Cisplatin treated mice showed scattered lymphocytes in and
around the vessel. Many neutrophils were also seen in the tubules
and interstitium i.e. pyelonephritis (Figure 8.1L).
Compared with control, the liver of the mice treated with 50 mg
AECHL-1 did not affect the normal architect. Mice treated with
100 mg AECHL-1 retained the normal architect of the liver
(Figure 8.1M–8.1O). In cisplatin treated mice however, extensive
necrosis of hepatocytes were seen. The arrow at the right side
shows dead hepatocytes and this pattern can be seen with a variety
of hepatotoxins, where focal hepatocytes necrosis with lympho-
cytic infiltration occurs. In these tissues, lesions look similar to that
of Tyzzer’s disease characterised by necrosis with varying degrees
of inflammation in response to the necrosis. Acute hepatic lesions
consist of necrotic foci surrounded by minimal, primarily
neutrophilic, inflammation (Figure 8.1P).
Representative spleen sections from Control and mice treated
with 50 mg AECHL-1 showed normal spleen architect and mice
treated with 50 mg AECHL-1. Control and mice treated with
100 mg AECHL-1 and cisplatin showed hyperplasia of the white
pulp, especially in the marginal zone (Y). Histology showed
increased number of granulocytes in the marginal zones
(Figure 8.1Q–8.1T).
Table 1. Cell cycle analysis of AECHL-1–treated cells.
Cell line Compound Conc. (mM) Phase of cell cycle (% of cells)
Sub G0 G1 SG 2/M
B16F10 AECHL-1 0 0.24 52.18 21.39 26.59
10 0.39 56.55 20.46 23.02
20 0.65 57.67 18.4 23.6
40 2.05 72.08 11.43 14.73
100 7.82 64.04 15.41 13.23
PC3 AECHL-1 0 1.44 55.65 15.21 27.7
10 1.66 50.74 16.21 30.94
20 1.79 48.96 13.99 34.99
40 4.14 44.26 17.71 33.82
100 3.36 39.02 20.25 37.37
MDA-231 AECHL-1 0 1.48 49.54 25.79 23.61
10 1.03 43.03 24.06 32.21
20 0.95 33.18 28.63 38.01
40 0.54 26.66 28.12 45.15
100 0.58 22.82 30.99 46.17
MCF-7 AECHL-1 0 1.64 53.67 19.03 26.1
4 1.61 35.04 27.2 36.65
10 1.99 27.85 34.19 36.78
20 1.81 29.68 37.44 31.98
40 2.55 36.26 32.5 29.42
MCF-7 Paclitaxel 0 3.17 48.3 20.42 29.3
1 3.45 4.62 18.65 72.55
2 5.21 7.41 22.89 63.71
5 3.98 5.34 18.35 72.86
10 3.47 4.86 18.96 69.36
Effect of AECHL-1 on cell cycle progression in B16F10, PC3, MDA-231, MCF-7
and paclitaxel in MCF-7 cells in 24 hr of treatment. Cell cycles were analyzed
using propidium iodide. DNA content was analyzed using FACS to determine
the cell cycle distribution.
doi:10.1371/journal.pone.0005365.t001
Figure 5. Effect of AECHL-1 on microtubules. MCF-7 cells were treated with the vehicle as a control, AECHL-1 (5 mM) and paclitaxel (5 mM) as a
positive control for 24 h, and microtubules (red) were visualized by indirect immunofluorescence. DAPI was used to stain the cell nuclei (blue).
Representative of 25–30 cells each in 3 separate experiments.
doi:10.1371/journal.pone.0005365.g005
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organs in nude mice
Tumors from control mice showed pronounced neovascular-
ization throughout the section surrounded by highly dense cells
and absence of necrotic cells (Figure 8.2A). AECHL-1 at 5 mg dose
showed decreased tumor cell density and lacunae throughout the
tumor area. It also showed loss of neovasulization and absence of
hemorrhagic areas (Figure 8.2B). AECHL-1 at 10 mg showed
many empty spaces, occurrence of hemorrhagic areas was seen but
reduction in the vasculization was not seen (Figure 8.2C).
Treatment with Paclitaxel lowered the tumor cell density with
occurrence of many empty spaces and necrotic areas in the section
(Figure 8.2D).
Treatment with 5 mg AECHL-1 did not show any change in the
normal myocardium, while 10 mg AECHL-1 and Paclitaxel
showed necrosis of myocardial fiber. Paclitaxel showed extensive
myocardial fiber necrosis with fragmentation and smudging of the
myocardium (Figure 8.2E–H). No significant change was observed
in kidney structure from AECHL-1 treated groups, while
paclitaxel treatment showed signs of tubular vacuolization dilation
with hemorrhagic areas (Figure 8.2I–8.1L). Both AECHL-1 and
Paclitaxel did not show any change in the normal architecture of
liver (Figure 8.2M–8.2P) and Spleen sections (Figure 8.2Q–8.2T).
Discussion
In the present study, we report a new anti-cancer compound
AECHL-1, isolated from root bark of the plant Ailanthus excelsa.
AECHL-1 was characterized by UV, IR, NMR and mass
spectroscopy and the purity was conformed by HPLC. It is a
triterpenoid with high polarity and a molecular weight 453.8
(Figure 1 and Figure 2). The tumor-suppressor gene p53 plays a
vital role in the development of various types of cancers. It is
estimated that 50% of all cancers develop due to mutations in p53
[21–23]. Therefore, we first tested the effect of AECHL-1
Figure 6. Effect of AECHL-1 on primary tumor volume in allograft and xenograft. (A) Photographs of C57BL/6 mice showing 4-week-old
allograft tumor growth by B16F10 cells; below, excised tumors with respective mice; (B) Tumor volume was determined at timed intervals as
described in ‘‘Materials and Methods’’. Tumor volume of experimental animals after treatment with 50, 100 mg AECHL-1 and 100 mg cisplatin was
compared with the tumor volume of control animals; (C) Photographs of athymic nude mice showing 4-week-old xenograft tumor growth by MCF-7
cells; below, excised tumors with respective mice; (D) Tumor volume of experimental animals after treatment with 5, 10 mg AECHL-1 and 20 mg
paclitaxel was compared with the tumor volume of control animals. Results represent the mean6SE of six starting animals in each group. Significant
differences between
*Intra group at each time point are represented as:
ns p.0.05,
*p,0.05,
**P,0.01,
***P,0.001 and
#Inter group at different doses
are represented as
ns P.0.05,
#,0.05,
##P,0.01,
###P,0.001.
doi:10.1371/journal.pone.0005365.g006
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with different tissue origin that contain either wild-type or mutant
p53, as well as p53 null. B16F10 and MCF-7 cells contain wild
type p53, MDA-MB-231 cells contain mutant p53 and PC3 cells
are p53 null. Cisplatin, a highly DNA damaging agent and
paclitaxel, a tubulin based anti-mitotic agent were used as positive
controls.
We found that AECHL-1 inhibited the growth of MCF-7 cells
in a concentration dependent manner at 12, 24 and 48 hr
(Figure 3A). Cytotoxicity was also observed in the other cancer
cells at 48 hr to a varying degree with a minimum growth
inhibition of a normal human embryonic kidney cell line, HEK-
293 (Figure 3B). The degree of cytotoxicity was MCF-
7.B16F10.PC-3.MDA-MB-231.HEK-293 (Figure 3B) and
inhibition of cell proliferation was MCF-7.B16F10.MDA-MB-
231.PC-3 (Figure 3C).
Compared with paclitaxel and cisplatin, AECHL-1 showed
greater potency in MCF-7 (Figure 3D), B16F10 and MDA-MB-
231 cell proliferation inhibition at 24 and 48 hr (data not shown).
These results indicate that in MCF-7, B16F10 and MDA-MB-231
cell line AECHL-1 is more effective in inhibition of cell
proliferation than cisplatin or paclitaxel. However, in PC-3 cells,
paclitaxel is more effective than cisplatin and AECHL-1.
In B16F10 cells, AECHL-1 was found to significantly induce
cell cycle arrest in G1 phase, while in MCF-7, MDA-MB-231 and
PC3 cells it showed arrest in S-G2/M phase in MCF-7 cells
(Table 1).
The cell cycle arrest in AECHL-1 treated MCF-7 cells was
followed by concentration dependent apoptosis, but the percent-
age of cell death was dependent on the types of cell lines.
Compared to B16F10 and MDA-MB-231 cells, AECHL-1 was
highly effective in MCF-7 cells at both high and low concentra-
tions (Figure 4).
Therapeutic interference with the mitotic spindle apparatus is a
widely used rationale for the treatment of tumors. The
microtubule network required for mitosis and cell proliferation
has been shown to be disrupted by the diterpenoid paclitaxel [24].
It has also been shown that microtubule disruption elevates p53
protein levels [25]. Our immunofluorescence staining of tubulin
showed that similar to paclitaxel, AECHL-1 inhibited microtubule
assembly (Figure 5).
Our in vitro results demonstrate that AECHL-1 can act as a
new class of microtubule damaging agent arresting cell cycle
progression at mitotic phase and inducing apoptosis. AECHL-1
was tested in vivo in C57BL/6 mice allograft with melanoma,
B16F10 and nude mice xenograft with human breast cancer cells,
MCF-7. Injections of AECHL-1 to the tumor sites were found to
inhibit tumor growth in both models. In case of B16F10
melanoma model, a daily dose of 50 mg and 100 mg showed a
significant antitumor effect, leading to regression of established
tumors (Figure 6A and 6B) however; cisplatin was more effective
than AECHL-1 but AECHL-1 showed less toxicity to kidney and
heart while cisplatin showed greater damage to kidney, heart, liver
and spleen (Figure 8.1). In the MCF-7 breast cancer model, a daily
dose of 5 and 10 mg showed a significant antitumor effect, leading
to regression of established tumors (Figure 6C and 6D).
In order to understand the major in vivo pathways through
which AECHL-1 may induce tumor suppression, we studied the
expression of the tumor suppressor, cell cycle regulatory proteins
and oncogene in B16F10 melanoma. Our in vitro cell cycle
analysis on B16F10 had showed a strong G1 arrest as a result of
AECHL-1 treatment. Furthermore, mechanistic investigation in
Figure 7. Effect of AECHL-1 on cell cycle regulatory proteins. Tumor tissue lysates were subjected to SDS-PAGE followed by Western
immunoblotting. Membranes were probed with anti-p53, pp53, p21, c-myc, cyclin D1, cdk4, and b-actin antibodies followed by peroxidase-
conjugated appropriate secondary antibodies, and visualized by enhanced chemiluminescence detection system. The experiments were repeated
thrice with similar results and a representative blot is shown for each protein.
doi:10.1371/journal.pone.0005365.g007
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cisplatin up regulated the expression of p53 (Figure 7). However,
AECHL-1 induced hyper phosphorylation of p53 at ser-15.
Phosphorylation of p53 at ser15 help in strongly binding p53 to
DNA for the up regulation of cell cycle regulatory proteins that
helps in suppression of the growth of tumor [26]. Cisplatin also up
regulated p53, but phosphorylation at ser-15 was not observed
(Figure 7). This may be due to the fact that cisplatin suppress the
growth of tumor cells by DNA damage and apoptosis [27]. The
observation that ser-15 phosphorylation is required for p21
induction prompted us to investigate its role in G1 arrest
[26,28]. We found an increase in the expression of p21 in the
AECHL-1 treated tumors. p21 forms a complex with CDK2/
CDK4/CDK6 and inhibit the CDK-cyclin kinase activity phase
[28,29] and arrest the cells in G1 phase. c-Myc is an oncogene that
is up regulated in cancer cells and help in the tumor growth [30].
We observed that treatment of AECHL-1 resulted in a marked
decrease in c-Myc, CDK-4 and cyclin D1 levels that is known to
arrest the cell in G1 [31]. Decreases level of c-Myc is known to be
involved in the down regulation of cyclin D1 and CDK4 [32]
(Figure 7). This also decreases the kinase activity and arrest the cell
in G1 phase.
In conclusion, our data clearly show that AECHL-1 is less
toxic, more selective, and more effective in the treatment of
cancer in comparison to plant derived anti-cancer compound
paclitaxel and metal-based compound cisplatin. It is efficacious in
inhibiting the proliferation of a broad range of cancer cells as
well as solid tumors. The novel compound AECHL-1 is found to
interact directly with tubulin, arrest the cell cycle, and induce
apoptosis of tumor cells. The antitumor effect of AECHL-1 was
comparable with or even superior to the conventional chemo-
therapeutic drugs tested. The positive outcomes of such an in
vitro and in vivo study could form a strong basis for the
development of AECHL-1 as a novel agent for human cancer
prevention and/or intervention.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0005365.s001 (154 KB TIF)
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Figure 8. Histological analysis of tumor tissue and other organs in C57BL/6 and nude mice. (1) Representative H&E-stained sections from
B16F10 allograft tumors and the characteristics of these tumors were analyzed (1A–1D). Morphological characteristics of heart (1E–1H), kidney (1I–1L),
liver (1M–1P) and spleen (1Q–1T), six mice were used in each set of experiments. (2) Representative H&E-stained sections from MCF-7 xenograft
tumors and the characteristics of these tumors were analyzed (2A–2D). Morphological characteristics of heart (2E–2H), kidney (2I–2L) and liver (2M–
2P), spleen (2Q–2T), three mice were used in each set of experiments.
doi:10.1371/journal.pone.0005365.g008
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